Contract Research & Services
Clinical Trials

Clinical Trials

Destiny Pharma’s XF-73 succeeds in phase 1 skin irritation study By PBR Staff Writer
Destiny Pharma, a UK-based clinical stage biotechnology company, has reported positive data for its synthetic antimicrobial drug XF-73 from a phase 1 skin irritation study.
Contract Research & Services > Clinical Trials > News
Evgen Pharma completes patient recruitment for breast cancer treatment trial Evgen Pharma, a clinical stage drug development company, has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.
Contract Research & Services > Clinical Trials > News Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial By PBR Staff Writer
Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Chi-Med starts phase Ib/II trial of sulfatinib in NET and BTC patients
By PBR Staff Writer
Hutchison China MediTech (Chi-Med) has commenced a phase Ib/II proof-of-concept study in the US to evaluate its small molecule angio-immuno kinase inhibitor sulfatinib in pancreatic neuroendocrine tumors (NET) and biliary tract cancer (BTC).
Contract Research & Services > Clinical Trials > News
Leap Therapeutics to evaluate TRX518/avelumab combo for advanced solid tumors
By PBR Staff Writer
Leap Therapeutics has signed a deal to evaluate its immuno-oncology compound TRX518 in combination with Merck and Pfizer’s avelumab, and chemotherapy for the treatment of advanced solid tumors.
Contract Research & Services > Clinical Trials > News
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
By PBR Staff Writer
Boehringer Ingelheim and Eli Lilly and Company reported that the CARMELINA cardiovascular outcome trial evaluating their diabetes drug Tradjenta met its primary endpoint.
Contract Research & Services > Clinical Trials > News
Takeda, Ovid plan to launch three trials of anti-epileptic drug TAK-935/OV935
Takeda Pharmaceutical and Ovid Therapeutics have revealed details of a clinical development program of their anti-epileptic drug TAK-935/OV935 in rare developmental and epileptic encephalopathies (DEE).
Contract Research & Services > Clinical Trials > News
Pfizer, Lilly’s osteoarthritis pain drug meets co-primary endpoints in phase 3 study
By PBR Staff Writer
Pfizer and Eli Lilly’s osteoarthritis (OA) pain drug, tanezumab, has met all three co-primary endpoints in a phase 3 study.
Contract Research & Services > Clinical Trials > News
Roche’s baloxavir marboxil succeeds in phase III flu study
By PBR Staff Writer
A phase III CAPSTONE-2 study has demonstrated that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu.
Contract Research & Services > Clinical Trials > News
Ironwood Pharmaceuticals starts Phase IIIb study of linaclotide in adult patients with IBS-C
Ironwood Pharmaceuticals has started a phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain, including bloating and discomfort, in adult patients with irritable bowel syndrome with constipation (IBS-C).
Contract Research & Services > Clinical Trials > News
Pfizer begins pivotal phase 3 program for investigational hemophilia B gene therapy
Pfizer and Spark Therapeutics announced that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting.
Contract Research & Services > Clinical Trials > News
AbbVie’s blood cancer drug Ibrutinib fails in phase 3 DLBCL trial
AbbVie’s Ibrutinib (IMBRUVICA) failed to meet its objective in a phase 3 trial DBL3001 in untreated diffuse large B-cell lymphoma (DLBCL) patients.
Contract Research & Services > Clinical Trials > News
Celgene’s anti-PD-L1 immunotherapy plus Abraxane improves PFS in breast cancer study
Celgene announced that the phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests